Halozyme Therapeutics, Inc. (HALO)
100.67
-1.01
(-0.99%)
USD |
NASDAQ |
Nov 12, 16:00
100.66
-0.01
(-0.01%)
After-Hours: 07:17
Halozyme Therapeutics Market Cap : 11.47B for Nov. 12, 2026
Market Cap Chart
Historical Market Cap Data
| Date | Value |
|---|---|
| November 12, 2026 | 11.47B |
| November 11, 2026 | 11.59B |
| November 10, 2026 | 11.73B |
| November 09, 2026 | 11.73B |
| November 06, 2026 | 11.81B |
| November 05, 2026 | 14.01B |
| November 04, 2026 | 14.85B |
| November 03, 2026 | 14.65B |
| November 02, 2026 | 14.71B |
| October 30, 2026 | 14.93B |
| October 29, 2026 | 14.96B |
| October 28, 2026 | 14.83B |
| October 27, 2026 | 14.65B |
| October 26, 2026 | 14.60B |
| October 23, 2026 | 14.33B |
| October 22, 2026 | 14.20B |
| October 21, 2026 | 14.24B |
| October 20, 2026 | 14.18B |
| October 19, 2026 | 13.97B |
| October 16, 2026 | 13.89B |
| October 15, 2026 | 13.86B |
| October 14, 2026 | 13.32B |
| October 13, 2026 | 12.50B |
| October 12, 2026 | 12.67B |
| October 09, 2026 | 12.59B |
| Date | Value |
|---|---|
| October 08, 2026 | 12.53B |
| October 07, 2026 | 12.63B |
| October 06, 2026 | 12.51B |
| October 05, 2026 | 12.35B |
| October 02, 2026 | 12.53B |
| October 01, 2026 | 12.20B |
| September 30, 2026 | 12.59B |
| September 29, 2026 | 12.72B |
| September 28, 2026 | 12.87B |
| September 25, 2026 | 12.99B |
| September 24, 2026 | 13.14B |
| September 23, 2026 | 12.82B |
| September 22, 2026 | 13.13B |
| September 21, 2026 | 12.71B |
| September 18, 2026 | 12.82B |
| September 17, 2026 | 12.51B |
| September 16, 2026 | 12.37B |
| September 15, 2026 | 12.12B |
| September 14, 2026 | 12.31B |
| September 11, 2026 | 12.23B |
| September 10, 2026 | 12.20B |
| September 09, 2026 | 12.25B |
| September 08, 2026 | 12.35B |
| September 04, 2026 | 12.57B |
| September 03, 2026 | 12.63B |
Market Capitalization Definition
Market Capitalization measures the total value of a company based on their stock price multiplied by the shares outstanding. This metric is important because it gives you an idea of the size of a company, and how the size has changed over time. When studying companies from a relative basis, it would make sense to compare companies that have a similar market capitalization because factors like market share, economies of scale, and business models would also be similar.
Market Cap Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Market Cap Benchmarks
| AVITA Medical, Inc. | 501.59M |
| Iovance Biotherapeutics, Inc. | 3.529B |
| Merck & Co., Inc. | 362.49B |
| Neurocrine Biosciences, Inc. | 17.16B |
| TG Therapeutics, Inc. | 9.759B |
Market Cap Related Metrics
| PE Ratio | 25.62 |
| PS Ratio | 6.763 |
| Price to Free Cash Flow | 13.76 |
| Price | 100.67 |
| Earnings Yield | 3.90% |
| Operating PE Ratio | 11.93 |
| Normalized PE Ratio | 16.69 |